Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
First previewed in the company’s May roadmap, the new withZeta.ai module now enters early access with leading bioinformatics teams and Lantern collaborators — autonomously designing experiments, building rigorous cohorts from 615,000+ curated cancer samples, and delivering publication-ready multi-omic analysis in minutes
A new class of research agent. ZetaOmics™ is an autonomous “Computational Biologist” that goes beyond automating software — it reasons about experimental design, prevents pitfalls that produce false discoveries, and makes statistically rigorous decisions on its own, encoding the judgment of a tenured bioinformatician so that scientific rigor is the default across rare and common cancers alike.
Intelligent discovery, analysis, and cohort-building at scale. Through direct access to more than 615,000 curated cancer samples across eleven data sources, ZetaOmics resolves fragmented data and vocabularies autonomously and builds meaningful, analysis-ready cohorts from natural-language questions — turning weeks of manual data wrangling into minutes.
